Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals, Inc. (MRNS)
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.marinuspharma.com/investor-relations
Company Research
Source: Business Wire
Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025TrustTSC maintained a double-blind discontinuation rate of 6.2% with 93% of patients continuing to the open-label extensionPatients who completed Marinus’ Phase 2 TSC trial and entered the long-term extension demonstrated a median reduction in seizure frequency of 56% within two years (n=9)Real-world claims data support a significant unmet need in TSC with approximately 26% of patients having tried and failed three or more antiseizure medicationsNotice of Allowance received from the USPTO for a patent application that claims ganaxolone oral titration regimens for treating a broad range of epilepsies; the patent is expected to grant shortly with a term that runs through September 2042 RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the develo
Show less
Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNS alerts
High impacting Marinus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MRNS
News
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year [Yahoo! Finance]Yahoo! Finance
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $10.00 price target on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.MarketBeat
MRNS
Earnings
- 8/13/24 - Miss
MRNS
Sec Filings
- 9/20/24 - Form 8-K
- 8/13/24 - Form 10-Q
- 8/13/24 - Form 8-K
- MRNS's page on the SEC website